Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

79.52
+2.142.77%
Volume:2.56M
Turnover:206.25M
Market Cap:3.88B
PE:-18.40
High:88.68
Open:81.30
Low:77.84
Close:77.38
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:2.86
T/O Rate:8.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-303.41
PE(LYR):-20.98

Loading ...

Guggenheim Keeps Their Buy Rating on Celcuity (CELC)

TIPRANKS
·
May 04

Celcuity Inc : H.c. Wainwright Raises to Buy From Neutral; Raises Target Price to $165 From $94

THOMSON REUTERS
·
May 04

Celcuity upgraded to Buy from Neutral at H.C. Wainwright

TIPRANKS
·
May 04

Celcuity price target raised to $160 from $150 at Citizens

TIPRANKS
·
May 04

Celcuity Is Maintained at Buy by Needham

Dow Jones
·
May 04

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Boston Scientific (BSX)

TIPRANKS
·
May 04

Celcuity Inc : Needham Raises Target Price to $155 From $122

THOMSON REUTERS
·
May 04

U.S. RESEARCH ROUNDUP- Alphabet, Colgate-Palmolive, Welltower

Reuters
·
May 04

Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint

TIPRANKS
·
May 02

Celcuity says Phase 3 VIKTORIA-1 meets primary endpoint in PIK3CA-mutant breast cancer

Reuters
·
May 02

Celcuity Inc - to Submit Viktoria-1 Data to FDA as Supplemental Nda

THOMSON REUTERS
·
May 02

Celcuity's Phase 3 Viktoria-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in Pik3CA Mutant Cohort

THOMSON REUTERS
·
May 02

Celcuity Inc - FDA Grants Priority Review for Gedatolisib Nda With Pdufa Date July 17, 2026

THOMSON REUTERS
·
May 02

Celcuity Inc - Gedatolisib Regimens Show Manageable Safety Profiles With No New Safety Signals

THOMSON REUTERS
·
May 02

Celcuity trading halted, news pending

TIPRANKS
·
May 02

Celcuity Initiated at Market Outperform by Citizens

Dow Jones
·
Apr 27

Celcuity initiated with an Outperform at Citizens

TIPRANKS
·
Apr 27

Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending

Simply Wall St.
·
Apr 08